ProCE Banner Activity

Experts Discuss Clinical Application of TRK Inhibitors and Tumor Agnostic NTRK Fusion Testing

Multimedia
Watch this on-demand Webcast from our live symposium to review the latest clinical data and expert perspectives on targeting TRK in solid tumors, available and emerging TRK inhibitors, and implementing NTRK fusion testing in practice.

Released: July 15, 2019

Expiration: July 13, 2020

Share

Faculty

Todd M. Bauer

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Marcia Brose

Marcia Brose, MD, PhD, FASCO

Professor
Department of Medical Oncology
Sidney Kimmel Medical College
Thomas Jefferson University
Director, Sidney Kimmel Cancer Center
Vice Chair, Medical Oncology
Sidney Kimmel Medical College
Jefferson Northeast
Philadelphia, Pennsylvania

George D. Demetri

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Learning Objectives

  • Describe the biology of and rationale for targeting cancers containing NTRK fusions
  • Identify patients with cancer who should be tested for NTRK fusions with established and emerging biomarker assays
  • Describe the research data supporting the use of TRK inhibition in a range of cancers harboring NTRK fusions
  • Formulate strategies for using TRK inhibitors in clinical practice once approved
  • Refer adult and pediatric patients to ongoing late-phase clinical trials of TRK inhibitors

Faculty Disclosure

Primary Author

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Todd M. Bauer, MD, has disclosed that has received funds for research support paid to his institution from AbbVie, Aileron, Amgen, Armo, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera, Clovis, Daiichi Sankyo, Deciphera, Five Prime, Foundation Medicine, Genentech, GlaxoSmithKline, Immunocore, ImmunoGen, Incyte, Ignyta, Jacobio, Janssen, Leap, Lilly, Loxo, Karyopharm, Kolltan, MabVax, MedImmune, Medpacto, Merck, Mirati, Merrimack, Millennium, Moderna, Novartis, Onyx, Peleton, Pfizer, Phosplatin, Principa, Roche, Sanofi, Stemline, Takeda, and Top Alliance BioScience; has received consulting fees paid to his institution from Ignyta, Leap, Loxo, and Moderna; has received consulting fees from Bayer, Guardan, Loxo, and Pfizer; and has served on the speaker bureau for Bayer.

Marcia Brose, MD, PhD, FASCO

Professor
Department of Medical Oncology
Sidney Kimmel Medical College
Thomas Jefferson University
Director, Sidney Kimmel Cancer Center
Vice Chair, Medical Oncology
Sidney Kimmel Medical College
Jefferson Northeast
Philadelphia, Pennsylvania

Marcia S. Brose, MD, PhD, has disclosed that she has received consulting fees from Bayer, Blueprint Medicines, and Loxo Oncology and funds for research support paid to her institution from AstraZeneca, Bayer, Blueprint Medicines, Eisai, Exelixis, Lilly, Loxo Oncology, and Novartis.

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

George D. Demetri, MD, has disclosed that he has received consulting fees and funds for research support from Bayer, Ignyta, Loxo Oncology, and Roche; has received consulting fees from AbbVie, Adaptimmune, Daiichi-Sankyo, EMD Serono, Epizyme, GlaxoSmithKline, ICON, Janssen, Lilly, Mirati, Novartis, Pfizer, PharmaMar, Polaris, Sanofi, and ZioPharm; has served as a consultant/scientific advisory board member with minor equity holding for Bessor, Caris Life Sciences, Champions Biotechnology, Erasca, and G1 Therapeutics; and has served as an independent member of the board of directors and scientific advisory board consultant with minor equity holding for Blueprint Medicines and Merrimack.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, has relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen M. Rosenthal, PhD, has no relevant conflicts of interest to report.

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.